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(PS 0-1), never smoker, and development of skin rash with geﬁtinib ( 
p<0.001, p=0.031, p<0.001, respectively). 
Conclusion: This analysis suggests that patients with good perfor-
mance status and never smoker and development of skin rash may 
beneﬁt from geﬁtinib treatment in terms of tumor response as well as 
survival. 
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Background: Geﬁtinib (Iressa) is active as a single agent in the 
treatment of select patients with recurrent non-small cell lung cancer 
(NSCLC). The clinical characteristics of patients treated with geﬁ-
tinib at our department identiﬁed predictive variables associated with 
survival .
Methods: Patients (n = 60) with advanced NSCLC were treated with 
geﬁtinib (250 mg) upon progression with chemotherapy. N-score=o is 
deﬁned as N0,N1 or no-bulky and single N2,N-score=1 is deﬁned as 
bulky or multiple N2 or N3 or distant lymph node.
Results: Partial responses were noted in 18 patients (30%) and disease 
stabilization in 25 (41.7%) patients. The median survival (MS) was 
51weeks and median time to progression was 24 weeks. The predic-
tive factors analyzed were gender,age, tumor histology, T,N, N-score, 
performance status (PS) and weight lost. Tumor histology (p=0.008) 
and N-score (P <0.001)(not N) were predict factors in Cox regression 
model .
Conclusions: Tumor histology and N-score could predict survival time 
for recurrent NSCLC patients treated with geﬁtinib 
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Cutaneous side-effects of erlotinib treatment in lung cancer 
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A new class of drugs that have the ability to inhibit the epidermal 
growth factor receptor (EGFR), namely geﬁtinib, erlotinib and cetux-
imab, is being used for treatment of patients with colorectal, head and 
neck, or non-small cell lung cancer (NSCLC) refractory or intolerant to 
chemotherapy.
Erlotinib (EGFR-speciﬁc tyrosine kinase inhibitor) is currently been 
used for the treatment of patients with locally advanced or metastatic 
NSCLC after failure of at least one previous chemotherapy regimen, it 
is taken orally and its most frequent undesirable side-effects are gastro-
intestinal disturbance and, cutaneous alterations (acneiform rash, skin 
dryness, paronychia, nasal or oral ulcers, urticariform rash and sebor-
rhoeic dermatitis), that are observed in 56% and 75%, respectively. 
This skin toxicity is a pharmacologic class effect rather than a hyper-
sensitivity reaction to the drug. It appears to imply a better response 
from the tumor to erlotinib and is dose dependent but not correlated 
with duration of therapy. 
Dermatologists have now the responsibility to assist usage of this new 
therapy without lowering of dosis so an effective oncologic manage-
ment is achieved.
We present 5 cases of patients that underwent erlotinib treatment for 
NSCLC that presented cutaneous alterations, namely an acneiform 
reaction, hirsutism and paronychia and how we manage them. We’ll 
emphasize on cumulative dosis of the drug, delay to the appearance 
of the cutaneous side effects and time needed for their remission after 
treatment. 
This work intends to point out the need for dermatologists to be aware 
of the new oncologic drugs that are being developed, the alterations 
they cause in the skin and the need for a consensus in how to treat them 
so we can help the patient comply with the oncologic treatment and 
hopefully improve its quality of life and survival. 
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Introduction: IMO-2055 is a novel synthetic oligonucleotide ago-
nist of TLR9 that stimulates innate and adaptive immune responses 
in preclinical studies. IMO-2055 was well tolerated in a phase 1 
monotherapy study in refractory solid tumor patients at dosages up to 
0.64 mg/kg/week SC, with optimal immune system activation, based 
on the parameters evaluated, demonstrated between 0.16 and 0.32 
mg/kg/week. Mild, transitory lymphocytopenia on day 2 (d2) was an 
expected pharmacology. Adverse events (AEs) were mild-moderate 
injection site reactions and ﬂu-like symptoms. In preclinical studies, 
IMO-2055 was shown to potentiate the activity of standard oncology 
therapies, including chemotherapy, monoclonal antibodies and targeted 
agents. Combining IMO-2055 with gemcitabine in a mouse NSCLC 
model (A549) led to greater suppression of tumor growth than either 
agent alone. The carboplatin-gemcitabine combination had acceptable 
activity and a different safety proﬁle vs. standard cisplatin-gemcitabine 
in NSCLC (Zatloukal et al, Lung Can 2003). Based on these data, we 
investigated the combination of IMO-2055, gemcitabine and carbopla-
tin in advanced solid tumor patients. 
Methods: We combined IMO-2055 at 4, 8 or 12mg total dose per SC 
injection with gemcitabine 1000mg d1 and 8 IV plus carboplatin AUC5 
d1 IV q3w. The initial IMO-2055 schedule was d1, 8, 15; schedules of 
d2, 9 and d9, 16 were added to optimize IMO-2055 administration rela-
tive to the nadirs of chemotherapy-induced hematological toxicity. Pts 
had refractory solid tumors with ≤ 2 prior regimens and fulﬁlled stan-
dard phase 1 entry criteria. The primary endpoint was to identify MTD; 
secondary endpoints included safety and response rate (RECIST). 
Results: 18 pts were treated from November 2005 to February 2007 for 
a median of 3 cycles (1-15) in 17 evaluable pts (7 male; 10 female): 7 
NSCLC, 3 neuroendocrine, 2 unknown primary, 1 each of melanoma, 
esophagus, head and neck, breast and cholangio- carcinomas. Median 
ECOG PS was 1 (0-1) with median 1 prior chemotherapy and 53% 
prior radiotherapy. Grade 4 neutropenia or thrombocytopenia have 
been identiﬁed as DLTs in 2/5 pts at IMO-2055 12mg d1, 8, 15; 2/3 pts 
at 8mg d2, 9; 1/2 pts at 12mg d9, 16; and 0/3 pts at 8mg d9, 16. Most 
